Publication Date: 19 Nov 2012
Type: Short Report
Journal: Immunotherapy Insights
Citation: Immunotherapy Insights 2012:3 1-7
doi: 10.4137/INT.S10365
New developments in cellular adoptive immunotherapy have led to tailor made therapies for cancer patients. One of the latter therapies is tumor antigen–specific T cell receptor (TCR) transfer enabling recognition of, for example, the hematopoietic restricted minor histocompatibility (H) antigen HA-1. Since HA-1 is also expressed on leukemic and leukemic progenitor cells, transfer of in vitro–generated HA-1 CTL or usage of HA-1 TCR-modified T cells will contribute to an anti-leukemic response. The fact that all thus far analyzed HA-1–specific T cells express the same TCR Vbeta TRBV7-9, makes this TCR an attractive candidate for TCR transfer studies. Here we show however different cytolytic capacity among the TRBV7-9 expressing HA-1–specific T cells. Consequently, functional in vitro studies of the relevant T cells prior to TCR transfer are highly recommended.
PDF (669.43 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I had an excellent experience with the professional editorial team at Libertas Academica. The entire process of submitting the review was easy and required little time. Every step was transparent with immediate responses. I'm really satisfied to have published our article with Libertas Academica.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2014 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
Facebook Google+ Twitter
Pinterest Tumblr YouTube